Another phase III trial focusing on the combination of ipatasertib and fulvestrant in metastatic HR-positive, HER2-negative breast cancer, in the context of progression after a first-line therapy with aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor, is ongoing to reinforce data on this AKT inhibitor [54]. The gene discussed is CDK4; the disease is breast cancer.